Skip to content
Screener

Bioventus BVS Preferred Stock, Shares Authorized

Preferred Stock, Shares Authorized at other companies

Xtant Medical Holdings logo
Xtant Medical HoldingsXTNT
$10M0.0%
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$5M
Artivion logo
ArtivionAORT
$5M0.0%
SI-BONE, Inc. logo
SI-BONE, Inc.SIBN
IAR
Integra LifeSciencesIART

Other financials

Income statement

See full
Revenue$153.2M+3.8%
Gross profit$105.7M+3.5%
Operating income$19.1M+4.1%
Net income$33.4M+348%
EPS (diluted)$0.47+327%

Balance sheet

See full
Cash & equivalents$29.5M-10.5%
Total debt$263.7M-26.9%
Total equity$228.3M+41.6%
Total assets$673.3M-4.7%

Cash flow

See full
Operating cash flow$19.9M-23.4%
CapEx$960.0K+40.6%
Free cash flow$18.9M-25.1%

Valuation

See full
Market cap$1.17B+153%
Enterprise value$1.41B+78.0%
P/E21.6×
P/S+1.2×

Profitability

See full
Gross margin68.7%+1.1pp
Operating margin10%
Net margin9.4%+9.2pp
FCF margin16.2%+10.2pp

Returns & leverage

See full
Return on equity28%+27.5pp
Debt / equity1.2×-1.1×
Current ratio1.7×+0.2×

Where this comes from

Reported directly by Bioventus in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The source filing: Bioventus’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:43 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001665988-26-000042
Line itemJune 27, 2026December 31, 2025
Total liabilities395,934455,112
Commitments and contingencies (Note 11)
Stockholders’ Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued
Class A common stock, $0.001 par value, 250,000,000 shares authorized as of June 27, 2026 and December 31, 2025, 68,211,818 and 67,097,716 shares issued and outstanding as of June 27, 2026 and December 31, 2025, respectively6867
Class B common stock, $0.001 par value, 50,000,000 shares authorized, 15,786,737 shares issued and outstanding as of June 27, 2026 and December 31, 20251616
Additional paid-in capital527,925520,851
Accumulated deficit(298,375)(334,929)

Item 1. Financial Statements (Unaudited)

FAQ

What is Bioventus's preferred stock, shares authorized?
Bioventus (BVS) reported preferred stock, shares authorized of $10M in Q2 2026.
How has Bioventus's preferred stock, shares authorized changed year-over-year?
Bioventus's preferred stock, shares authorized decreased by 0.0% year-over-year, from $10M to $10M.
What is the long-term trend for Bioventus's preferred stock, shares authorized?
Over 4 years (2021 to 2025), Bioventus's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $10M to $10M.
What does preferred stock, shares authorized mean?
Preferred Stock, Shares Authorized

Ask your AI about Bioventus's preferred stock, shares authorized.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude